Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LRBTR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AZD4360
|
|||||
| Synonyms |
AZD4360
Click to Show/Hide
|
|||||
| Organization |
AstraZeneca (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Antibody Name |
Anti-CLDN18.2 antibody
|
Antibody Info | ||||
| Antigen Name |
Claudin-18.2 (CLDN18.2)
|
Antigen Info | ||||
| Payload Name |
TOP1 inhibitor
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The indication landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Gastroesophageal junction adenocarcinoma |
1 Trials
|
|||||
| Gastric cancer |
1 Trials
|
|||||
| Pancreatic cancer |
1 Trials
|
|||||
| Biliary tract cancer |
1 Trials
|